Background: Leptomeningeal metastases (LM) are more frequent in NSCLC with EGFR mutations；and cerebrospinal fluid (CSF) could reveal the unique genetic profiles of LM in our previous studies, but whether they could predict the overall survival (OS) of LM remains unknown. Method: EGFR-mutant NSCLC patients with LM were enrolled, and clinical data and genetic profiles detected by Next-generation sequencing were collected. We further drew nomogram with endpoint of OS after LM, then performed index of concordance (C-index) and survival analysis to evaluate predictive role. Result: In total, 61 patients were enrolled and all with genetic profiles from CSF. Patents with high copy number variations (CNVs) or harboring CDK6, TP53 exon5 or FGF19 in CSF demonstrated significant poorer OS than those without (Fig. 1) . Cox regression analysis indicated CNVs, CDK6, CDKN2A, TP5, MET and NTRK1 as prognostic factors and further selected for nomogram ( Fig. 2 ). C-index of nomogram was 0.743, indicating the moderate predictive effect. In the calibration curves, we scored the patients based on the model, using bisection and trisection methods to divide into low and high points groups; and low, medium and high points groups (Fig. 3 ), and significant difference were found in both the survival analyses (NA versus 7.47months, P<0.01) and (NA, 10.33 versus 4.43 months, P<0.01) respectively. Patients who received Osimertinib after LM seemed to have longer OS than those who did not (14.5 months versus 7.7 months) but without significant difference(P＝ 0.10); however interestingly, in those with EGFR T790M negative who took Osimertinib after LM by themselves obtained survival benefit than those who did not(NA versus 7.7 months, P¼0.04), and the results needed to be validated. Background: Although human epidermal growth factor receptor 2 (HER2, ERBB2) genomic aberration has been identified as therapeutic targets, clinical trials of HER2-directed therapies have disappointing results in lung cancer. We hypothesize that the concurrent alterations might be one of the reasons, thus the aim of this study was to describe frequent concurrent alterations in Chinese lung cancer patients harboring HER2 mutations. Method: A total of 147 cancer patients with HER2 mutations were enrolled in the study. Tumor biopsy, ctDNA and pleural effusion samples were collected for detection alterations using hybridization capture based next-generation sequencing (NGS), which enables the simultaneous detection of single-nucleotide variants, insertions/deletions, rearrangements, and copy-number alterations of at least 59 genes (59-1021). Result: Sixtytwo of 147 patients with HER2 genomic aberrations were diagnosed as lung cancer. The HER2 gene was amplified in 11 (18%) patients, whereas HER2 mutations were detected in 48 patients, co-occurrence of HER2 amplification and mutations were in 3 patients. Thirty of the 62 patients (48.39%) had concurrent actionable mutations across 18 genes, which involved in RTK-PIK3CA-mTOR signaling pathways, cellcycle pathway, DNA repair pathway, RAS-RAF-MAPK pathway and some others (details in table). Moreover, 7 patients had more than 2 concurrent mutations besides HER2 mutation/amplification. Conclusion: Concurrent of actionable genetic alterations in HER2altered Chinese lung cancer patients was common. The complex molecular profiles elucidate the importance of comprehensive analysis of genetic mutations when considering anti-HER2 targeted therapy. Keywords: HER2-mutant LC, concurrent gene alterations, next generation sequencing (NGS) Background: The brain is a common site for metastasis in nonsmall-cell lung cancer (NSCLC), causing poor prognosis and reducing quality of life. This meta-analysis was designed to evaluate the relationship between the mutational status of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC patients with brain metastases. Method: Electronic searches were performed in PubMed, EmBase, and the Cochrane Library to identify studies evaluating the association of EGFR mutation with OS in NSCLC patients with brain metastases through September 2017. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to calculate the summary results using random-effects models. Sensitivity, subgroup, and publication bias tests were also conducted. Result: This meta-analysis identified 18 studies involving 4,373 NSCLC patients with brain metastases. The summary results indicated that mutated EGFR associated with significantly improved OS compared with wild type EGFR (HR: 0.73; 95%CI: 0.54-0.99; P ¼ 0.045). Subgroup analyses suggested that this relationship persisted in studies conducted in Eastern countries (HR: 0.59; P ¼ 0.021), in studies with retrospective design (HR: 0.70; P ¼ 0.004), with sample size 500 (HR: 0.52; P ¼ 0.001), mean age of patients 65.0 years (HR: 0.59; P ¼ 0.043), percentage male < 50.0% (HR: 0.60; P ¼ 0.002), percentage of patients receiving tyrosine kinase inhibitor 30.0% (HR: 0.60; P < 0.001), and in studies with higher quality (HR: 0.67; P ¼ 0.007). Finally, although significant publication bias was observed using the Egger test (P ¼ 0.008), the results were not changed after adjustment using the trim and fill method (HR: 0.73; 95%CI: 0.54-0.99; P ¼ 0.045). Conclusion: This meta-analysis suggests that EGFR mutation is an important predictive factor linked to improved OS for NSCLC patients with brain metastases. It can serve as a useful index in the prognostic assessment of NSCLC patients with brain metastases. Background: ALK-rearranged NSCLC is a unique molecular subgroup with high sensitivity to ALK inhibitors. Crizotinib, a FDA-approved tyrosine kinase inhibitor for ALK-rearranged NSCLCs, showed remarkable response in ALK-positive NSCLC. However, the magnitude and duration of clinical responses to crizotinib among different ALK variants are found to be heterogeneous, and studies about the clinical outcomes showed contradict conclusions. Method: We collected sequencing information from 110 ALK-positive Chinese NSCLC patients, whose tissue or plasma biopsies were sequenced in a CLIA-certified genomic profiling laboratory. Sequencing results were reviewed with the intent of studying ALK rearrangement distribution and clinical outcomes to crizotinib. Result: A total of 134 ALK rearrangements were identified in this cohort, with 39 unique rearrangements. EML4 was the most common ALK rearrangement partner, with variant 3 (v3) as the most frequent variants (42.7%) of EML4-ALK fusion, accounting for 71.6% (96/134) of all the rearrangements in 87.3% (96/110) patients. For EML4-ALK positive patients after crizotinib treatment (n¼96), survival analysis revealed that patients with EML4-ALK only displayed favorable PFS (10.0 vs 7.2 months, p¼0.037) and OS (36.0 vs 20.0 months, p¼0.037) than those combined with other fusions. In vitro data reported that variant v3 and v5 was structurally stable and less sensitive to ALK inhibitors due to the lack of TAPE domain. In this study, patients harboring v3 and v5 displayed significantly inferior OS than those with other variants (31 vs 37.6 months, p¼0.010). For all the ALKrearranged patients (n¼110), no significant difference was observed between the survival of EML4-ALK and non-EML4-ALK (PFS, 9.4 
